CL2014001399A1 - Compuestos de reversion anticoagulante; composicion farmaceutica y el uso de los mismos para revertir el efecto anticoagulante de un inhibidor de la coagulacion. - Google Patents
Compuestos de reversion anticoagulante; composicion farmaceutica y el uso de los mismos para revertir el efecto anticoagulante de un inhibidor de la coagulacion.Info
- Publication number
- CL2014001399A1 CL2014001399A1 CL2014001399A CL2014001399A CL2014001399A1 CL 2014001399 A1 CL2014001399 A1 CL 2014001399A1 CL 2014001399 A CL2014001399 A CL 2014001399A CL 2014001399 A CL2014001399 A CL 2014001399A CL 2014001399 A1 CL2014001399 A1 CL 2014001399A1
- Authority
- CL
- Chile
- Prior art keywords
- anticoagulant
- reversion
- reverse
- compounds
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161564559P | 2011-11-29 | 2011-11-29 | |
| US201261614292P | 2012-03-22 | 2012-03-22 | |
| US201261641698P | 2012-05-02 | 2012-05-02 | |
| US201261666291P | 2012-06-29 | 2012-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014001399A1 true CL2014001399A1 (es) | 2014-11-03 |
Family
ID=47430065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014001399A CL2014001399A1 (es) | 2011-11-29 | 2014-05-27 | Compuestos de reversion anticoagulante; composicion farmaceutica y el uso de los mismos para revertir el efecto anticoagulante de un inhibidor de la coagulacion. |
Country Status (35)
| Country | Link |
|---|---|
| US (4) | US9522892B2 (es) |
| EP (1) | EP2785700B1 (es) |
| JP (1) | JP6134731B2 (es) |
| KR (1) | KR101892330B1 (es) |
| CN (1) | CN104080772B (es) |
| AP (1) | AP2014007662A0 (es) |
| AR (1) | AR089020A1 (es) |
| AU (1) | AU2012345975B2 (es) |
| BR (1) | BR112014012892B1 (es) |
| CA (1) | CA2856540C (es) |
| CL (1) | CL2014001399A1 (es) |
| CO (1) | CO6990738A2 (es) |
| CR (1) | CR20140310A (es) |
| CY (1) | CY1117414T1 (es) |
| DK (1) | DK2785700T3 (es) |
| EA (1) | EA027603B1 (es) |
| EC (1) | ECSP14006696A (es) |
| ES (1) | ES2569674T3 (es) |
| HK (1) | HK1202858A1 (es) |
| HR (1) | HRP20160513T1 (es) |
| HU (1) | HUE027452T2 (es) |
| IL (1) | IL232788B (es) |
| ME (1) | ME02424B (es) |
| MX (1) | MX349514B (es) |
| PE (1) | PE20141295A1 (es) |
| PH (1) | PH12014501176A1 (es) |
| PL (1) | PL2785700T3 (es) |
| PT (1) | PT2785700E (es) |
| RS (1) | RS54738B1 (es) |
| SG (1) | SG11201402713WA (es) |
| SI (1) | SI2785700T1 (es) |
| SM (1) | SMT201600161B (es) |
| UA (1) | UA116336C2 (es) |
| WO (1) | WO2013082210A1 (es) |
| ZA (1) | ZA201404793B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9999690B2 (en) | 2013-11-08 | 2018-06-19 | Perosphere Pharmaceuticals Inc. | Labeled compounds and methods of imaging, diagnosing cartilage disorders and diseases, and monitoring cartilage health using labeled and unlabeled compounds |
| BR112019027735A8 (pt) * | 2017-11-13 | 2020-10-13 | Maximum Fidelity Surgical Simulations Llc | reconstituição de circulação pós-morte, métodos e procedimentos especializados |
| MX2021000127A (es) | 2018-06-29 | 2021-03-29 | Incyte Corp | Formulaciones de un inhibidor de axl/mer. |
| US11716989B2 (en) | 2019-04-16 | 2023-08-08 | Maximum Fidelity Surgical Simulations, LLC | Cadaver preservation systems and methods |
| US11915610B2 (en) | 2019-05-15 | 2024-02-27 | Maximum Fidelity Surgical Simulations, LLC | Cadaverous heart model |
| CN112010930B (zh) * | 2019-05-28 | 2022-08-02 | 首都医科大学 | Rgd修饰的五环哌嗪二酮及其制备和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3678157A (en) * | 1968-10-23 | 1972-07-18 | Oreal | Hair treatment compositions containing polycondensable compounds |
| IL115420A0 (en) * | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
| US6069232A (en) * | 1995-10-02 | 2000-05-30 | Hoechst Marion Roussel, Inc. | Polyfluoroalkyl tryptophan tripeptide thrombin inhibitors |
| US6080852A (en) | 1996-06-27 | 2000-06-27 | The Perkin-Elmer Corporation | 4,7-dichlororhodamine dyes |
| WO1998016547A1 (en) | 1996-10-11 | 1998-04-23 | Cor Therapeutics, Inc. | SELECTIVE FACTOR Xa INHIBITORS |
| CA2285454A1 (en) * | 1997-04-07 | 1998-10-15 | Axys Pharmaceuticals Corporation | Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, activity |
| FR2781221B1 (fr) * | 1998-07-17 | 2000-10-13 | Lafon Labor | Piperazinones substituees en alpha |
| EP1058549A4 (en) * | 1998-12-23 | 2003-11-12 | Bristol Myers Squibb Pharma Co | FACTOR Xa OR THROMBIN INHIBITORS |
| CN1152023C (zh) | 1999-05-19 | 2004-06-02 | 法玛西雅公司 | 作为抗凝血剂的取代的多环芳基与杂芳基尿嘧啶 |
| EP1377554A1 (en) * | 1999-06-16 | 2004-01-07 | University Of Iowa Research Foundation | Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases |
| JP2004501077A (ja) | 2000-04-17 | 2004-01-15 | ファルマシア・コーポレーション | 凝固カスケードの選択的阻害に有用な多環式アリールおよびヘテロアリール置換１，４−キノン |
| CA2413241A1 (en) * | 2000-06-29 | 2002-01-10 | Bristol-Myers Squibb Pharma Company | Thrombin or factor xa inhibitors |
| US6969715B2 (en) | 2001-10-03 | 2005-11-29 | Pharmacia Corporation | 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade |
| AU2003217028A1 (en) * | 2002-03-27 | 2003-10-13 | Cambridge University Technical Services Ltd | Diaminoacid-aminoacid-polyamine based gemini surfactant compounds |
| US20060233786A1 (en) * | 2002-05-23 | 2006-10-19 | Chugai Seiyaku Kabushiki Kaisha | Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation |
| GB0214122D0 (en) * | 2002-06-19 | 2002-07-31 | Eastman Kodak Co | High contrast photographic element containing a polyhydrazide nucleating agent |
| SE0400014D0 (sv) * | 2004-01-08 | 2004-01-08 | Astrazeneca Ab | Heterocyclic derivatives |
| US20060045865A1 (en) | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
| ES2849426T3 (es) * | 2007-09-28 | 2021-08-18 | Alexion Pharma Inc | Antídotos para inhibidores del factor Xa y procedimientos de uso de los mismos |
| GB2476643B (en) | 2009-12-23 | 2012-11-14 | Haomamedica Ltd | 1,4-Dihydro-1,4-dioxonaphtalene derivatives as anticoagulants |
| TWI513466B (zh) | 2010-01-20 | 2015-12-21 | Boehringer Ingelheim Int | 抗凝血劑解毒劑 |
| WO2012130834A1 (en) | 2011-03-30 | 2012-10-04 | Boehringer Ingelheim International Gmbh | Anticoagulant antidotes |
-
2012
- 2012-11-29 AP AP2014007662A patent/AP2014007662A0/xx unknown
- 2012-11-29 AU AU2012345975A patent/AU2012345975B2/en active Active
- 2012-11-29 PT PT128062296T patent/PT2785700E/pt unknown
- 2012-11-29 PL PL12806229.6T patent/PL2785700T3/pl unknown
- 2012-11-29 PE PE2014000763A patent/PE20141295A1/es active IP Right Grant
- 2012-11-29 EA EA201490823A patent/EA027603B1/ru unknown
- 2012-11-29 SI SI201230558A patent/SI2785700T1/sl unknown
- 2012-11-29 CN CN201280060950.2A patent/CN104080772B/zh active Active
- 2012-11-29 AR ARP120104474A patent/AR089020A1/es active IP Right Grant
- 2012-11-29 KR KR1020147016304A patent/KR101892330B1/ko active IP Right Grant
- 2012-11-29 ME MEP-2016-95A patent/ME02424B/me unknown
- 2012-11-29 UA UAA201404997A patent/UA116336C2/uk unknown
- 2012-11-29 SG SG11201402713WA patent/SG11201402713WA/en unknown
- 2012-11-29 RS RS20160318A patent/RS54738B1/sr unknown
- 2012-11-29 ES ES12806229.6T patent/ES2569674T3/es active Active
- 2012-11-29 MX MX2014006349A patent/MX349514B/es active IP Right Grant
- 2012-11-29 CA CA2856540A patent/CA2856540C/en active Active
- 2012-11-29 DK DK12806229.6T patent/DK2785700T3/en active
- 2012-11-29 BR BR112014012892-8A patent/BR112014012892B1/pt active IP Right Grant
- 2012-11-29 US US13/688,442 patent/US9522892B2/en active Active
- 2012-11-29 EP EP12806229.6A patent/EP2785700B1/en active Active
- 2012-11-29 HU HUE12806229A patent/HUE027452T2/en unknown
- 2012-11-29 WO PCT/US2012/066938 patent/WO2013082210A1/en active Application Filing
- 2012-11-29 JP JP2014544857A patent/JP6134731B2/ja active Active
-
2014
- 2014-05-26 IL IL232788A patent/IL232788B/en active IP Right Grant
- 2014-05-26 PH PH12014501176A patent/PH12014501176A1/en unknown
- 2014-05-27 CL CL2014001399A patent/CL2014001399A1/es unknown
- 2014-06-26 CR CR20140310A patent/CR20140310A/es unknown
- 2014-06-26 EC ECIEPI20146696A patent/ECSP14006696A/es unknown
- 2014-06-26 CO CO14137450A patent/CO6990738A2/es unknown
- 2014-06-27 ZA ZA2014/04793A patent/ZA201404793B/en unknown
-
2015
- 2015-04-01 HK HK15103329.9A patent/HK1202858A1/xx unknown
-
2016
- 2016-04-25 CY CY20161100338T patent/CY1117414T1/el unknown
- 2016-05-13 HR HRP20160513TT patent/HRP20160513T1/hr unknown
- 2016-06-08 SM SM201600161T patent/SMT201600161B/it unknown
- 2016-11-10 US US15/348,348 patent/US9877961B2/en active Active
-
2017
- 2017-10-06 US US15/726,497 patent/US20180207152A1/en not_active Abandoned
-
2020
- 2020-12-10 US US17/117,559 patent/US20210169874A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014001291A1 (es) | Agentes de iarn de doble hebra; composiciones y metodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr). | |
| CR20140259A (es) | Compuestos novedosos de benzopirano, composiciones y usos de los mismos | |
| LTC2924034I2 (lt) | Farmacinė kompozicija, apimanti nenukleozidinį atvirkštinės transkriptazės inhibitorių | |
| GT201400147A (es) | Pirimidinas y triazinas fusionadas sustituidas y su uso | |
| CL2014002093A1 (es) | Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas. | |
| BR112013018877A2 (pt) | composições farmacêuticas que compreendem anticorpos humanos para pcsk9 | |
| BR112014001255A2 (pt) | composto, uso de um composto, combinação, e, composição farmacêutica | |
| DK3192501T3 (da) | Topisk farmaceutisk sammensætning baseret på semifluorerede alkaner | |
| CO6801774A2 (es) | Compuestos de benzotiazol y su uso farmacéutico | |
| CO7020907A2 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas y métodos de uso de los mismos | |
| CL2013001947A1 (es) | Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona. | |
| BR112014029530A2 (pt) | compostos, composição farmacêutica e uso de um composto | |
| DK2694038T3 (da) | Farmaceutisk sammensætning | |
| CL2013000801A1 (es) | Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion | |
| BR112014005669A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112015000420A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| GT201400085A (es) | Profármaco de adrenomedulina basado en polietilenglicol y su uso | |
| BR112014023200A2 (pt) | uso de uma composição | |
| BR112014003567A2 (pt) | composto, uso de um composto, e, composição farmacêutica | |
| BR112015007310A2 (pt) | compostos, composição farmacêutica, uso de um composto de fórmula (i) e uso de uma composição farmacêutica | |
| CL2014001399A1 (es) | Compuestos de reversion anticoagulante; composicion farmaceutica y el uso de los mismos para revertir el efecto anticoagulante de un inhibidor de la coagulacion. | |
| CO6940429A2 (es) | Compuestos heterocíclicos, medicamentos que los contienen, uso de aquellos y procesos para su preparación | |
| CL2014001016A1 (es) | Compuestos triciclicos condensados y sus sales farmaceuticamente aceptables; composicion farmaceutica que los comprende; y su uso en el tratamiento de una infeccion viral. | |
| BR112014013177A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| CL2013000734A1 (es) | Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para bajar la presion intraocular; kit farmaceutico. |